ROSEN, LEADING INVESTOR COUNSEL, Encourages Capricor Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – CAPR

Core Viewpoint - Rosen Law Firm has announced a class action lawsuit on behalf of purchasers of Capricor Therapeutics, Inc. securities during the specified Class Period, alleging that the company provided misleading information regarding its lead drug candidate, deramiocel, which led to artificially inflated stock prices [1][5]. Group 1: Lawsuit Details - The class action lawsuit is filed for securities purchased between October 9, 2024, and July 10, 2025, inclusive [1]. - The lawsuit claims that Capricor provided materially misleading information about deramiocel, including its potential to obtain a Biologics License Application from the FDA, while concealing adverse facts about its safety and efficacy data from a Phase 2 trial [5]. - Investors are encouraged to join the class action without any out-of-pocket fees through a contingency fee arrangement [2]. Group 2: Next Steps for Investors - Interested investors can join the class action by visiting the provided link or contacting the law firm directly for more information [3][6]. - A lead plaintiff must be appointed by September 15, 2025, to represent the class in the litigation [1][3]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including the largest against a Chinese company at the time [4]. - The firm has consistently ranked highly in securities class action settlements and has recovered hundreds of millions for investors [4].